SG Americas Securities LLC Has $1.29 Million Holdings in Celldex Therapeutics, Inc. $CLDX

SG Americas Securities LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 143.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 47,340 shares of the biopharmaceutical company’s stock after acquiring an additional 27,872 shares during the quarter. SG Americas Securities LLC’s holdings in Celldex Therapeutics were worth $1,286,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CLDX. Vestal Point Capital LP increased its position in Celldex Therapeutics by 781.0% during the second quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $35,612,000 after buying an additional 1,551,354 shares during the last quarter. Braidwell LP bought a new stake in shares of Celldex Therapeutics during the third quarter worth approximately $15,307,000. Wellington Management Group LLP boosted its holdings in shares of Celldex Therapeutics by 10.8% during the third quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock worth $150,046,000 after acquiring an additional 567,677 shares during the period. Eventide Asset Management LLC boosted its holdings in shares of Celldex Therapeutics by 37.1% during the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after acquiring an additional 502,909 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Celldex Therapeutics by 104.3% during the third quarter. Millennium Management LLC now owns 975,195 shares of the biopharmaceutical company’s stock worth $25,228,000 after acquiring an additional 497,968 shares during the period.

Celldex Therapeutics Trading Down 0.1%

Shares of CLDX stock opened at $31.35 on Wednesday. The stock has a market cap of $2.09 billion, a P/E ratio of -8.06 and a beta of 1.19. The stock has a 50 day simple moving average of $27.89 and a 200 day simple moving average of $26.85. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $34.52.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CLDX shares. Stifel Nicolaus restated a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. The Goldman Sachs Group boosted their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Barclays boosted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $44.45.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.